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Infectious diseases continue to impact human morbidity and mortality. The massive 
explosions of tourism with an estimated 2 billion passengers each year on commercial airlines 
and rapid globalization have facilitated the spread of disease-causing pathogens from one 
continent to another at unprecedented rates. According to the World Health Organization, at 
least 40 new diseases have emerged over the past two decades, at a rate of one or more per 
year.  
 
Antimicrobial drugs have been instrumental in saving the lives of millions of people 
worldwide. The effectiveness of many antibiotics is, however, being steadily eroded by the 
emergence of drug resistant microorganisms [1] with the WHO declaring that antibiotic 
resistance is amongst the three greatest challenges to human health. About 25000 patients die 
each year in the EU from infections with multidrug-resistant bacteria according to the 
European Medicines Agency causing extra healthcare costs and productivity losses of at least 
EUR 1.5 billion each year. Crucial drug choices for the treatment of common infections by 
bacteria, viruses, parasites, and fungi are becoming limited and even nonexistent in some 
cases [2]. This development has not been paralleled by an effective increase in the discovery 
of new drugs for most pathogens and the rate of new
 
antimicrobials approvals is steadily 
dropping. The struggle to control infectious diseases, far from being over, has acquired a new 




The immune system can be manipulated specifically by vaccination or non-specifically by 
immunomodulation. Biological response modifiers or immunomodulators include both 
immunostimulatory and immunosuppressive agents. This chapter will concentrate on 
immunostimulatory agents capable of enhancing host defense mechanisms to provide 
protection against infections. Other synonymous terms for biological response modifiers 
include immunostimulants, immunoaugmentors, or immunorestoratives. Their modes of 
action include augmentation of anti-infectious immunity by the cells of the immune system 
encompassing lymphocyte subsets, macrophages, dendritic and natural killer cells. Further 
mechanisms can involve induction or restoration of immune effector functions and tilting the 
balance towards cytokine pathways germane to protection. A diverse array of recombinant, 
synthetic, and natural immunomodulatory preparations for prophylaxis and treatment of 




Cytokines, hormone-like polypeptides possessing pleiotropic properties, are crucial in 
orchestrating the appropriate immune responses critical for the outcome of an infection. 
Certain cytokines stimulate the production of other cytokines and interact in synergistic or 
antagonistic networks enabling manipulation of the host response to enhance overall 
immunogenicity and direct the nature of the response either toward type 1 or type 2 pathways. 
In the type 1 response, Th1 cells produce interferon (IFN) - , tumor necrosis factor (TNF) and 
interleukin (IL)-12 that are required for effective development of cell-mediated immune 
responses to intracellular microbes. In the type 2 response, Th2 cells produce IL-4, IL-5 and 
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IL-13 that enhance humoral immunity to T-dependent antigens and are necessary for 
immunity to helminth infections. Recent studies have shown that toll-like receptors (TLR), 
mainly found on dendritic cells (DCs) and macrophages, are important in transition from 
innate to adaptive immunity.  
In humans, DCs are subdivided into plasmacytoid DCs, which secrete copious amounts of 
IFN- , and myeloid DCs. Both subtypes of DCs recognize diverse microbial pathogens 
through specific TLR. Local and systemic effects of cytokines are, thus, intimately involved 
in the host control of infections. Several recombinant and natural cytokine preparations such 
as, interferons, and granulocyte colony-stimulating factor are already licensed for use in 
patients. 
 
INTERFERONS AND COMBINATIONS 
 
Interferon (IFN) was the first cytokine to be produced by the recombinant DNA technology. 
There are two classes of interferon, type I and type II. The type I IFN is produced in response 
to a viral infection and includes IFN-α and IFN-β. Most of the IFN-α in human is released by 
plasmacytoid dendritic cells whereas IFN-β is produced by fibroblasts and many other cell 
types. The type II IFN is secreted by activated T cells and NK cells as IFN-  also known as 
immune interferon.  
 
Interferon-alpha (IFN- ) is a clinically effective therapy used in a wide range of viral 
infections besides its application in malignant melanoma, basal cell carcinoma and warts. 
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Natural IFN-  obtained from human serum and leukocytes is currently licensed for the 
treatment of a rare form of cancer, hairy cell leukemia. Recombinant IFN- 2a is licensed for 
treatment of chronic active hepatitis B and for hepatitis C virus infections.  
 
Standard IFN-α has the drawbacks of a short serum half-life and rapid clearance. To 
overcome this problem, pegylated forms of IFN (PegIntron or Pegasys) have been developed 
and tested clinically. The greater polymer size of pegylated IFN acts to reduce glomerular 
filtration, markedly prolonging its serum half-life (72-96 hours) compared with standard IFN 




Hepatitis B virus (HBV) infection is widespread throughout the world infecting around 400 
million people and killing between 1 and 2.5 million people a year. The virus, transmitted by 
blood or body fluids, is up to 100 times more infectious than HIV. Overall, 15 to 25% of 
HBV carriers die from chronic hepatitis, cirrhosis or hepatocellular carcinoma (HCC) which 
accounts for up to 90 percent of all liver cancers.  
 
At present, licensed therapies widely used for treating liver disease caused by HBV include 
IFN-α, antiviral drugs lamivudine, adefovir and entecavir [8]. Most of these therapies are 
limited in the clinic by a low response rate, with only a small subset of patients with hepatitis 




Several promising studies have shown the effectiveness of pegylated interferon combination 
therapy with lamivudine or adefovir [9] with a better cost-benefit ratio. Interferon-  is also 
approved for treating condyloma acuminata caused by human papilloma virus and for Kaposi 
sarcoma in patients with HIV infection. Besides pegylated interferon, newer drug 
formulations demonstrated in clinical trials to be active against HBV include tenofovir, 
telbivudine and clevudine. 
 
Hepatitis C virus (HCV) is the major ecological agent of post-transfusion and community-
acquired non-A, non-B hepatitis infecting over 200 million people worldwide. Combination 
therapy with pegylated IFN and ribavirin (Pegetron) is the current standard of care for the 
treatment of chronic HCV infection. Recently, patients with a particular polymorphism
 
of a 
gene called IL28B have been shown to respond more favorably to treatment [10]. The FDA is 
expected to approve two protease
 





Interferon-  (IFN- ) obtained from human FS-4 fibroblast cell lines is licensed for use in 
severe uncontrolled virus-mediated diseases in cases of viral encephalitis, herpes zoster and 
varicella in immunosuppressed patients. A further indication is viral infection of the inner ear 
with loss of hearing. The standard treatment for multiple sclerosis, a disease without 




Interferon-  (IFN- ) is the major mediator of host resistance during the acute and chronic 
phases of infection and is pivotal in protection against a variety of intracellular pathogens. 
Multicenter clinical trials have shown that sustained administration of IFN-  to chronic 
granulomatous disease patients markedly reduced the relative risk of serious infection. IFN-  
is licensed as a therapeutic adjunct for use in patients with chronic (septic) granulomatosis for 
reduction of the frequency of serious infections. Imukin and Actimmune™ are IFN-  
preparations marketed for chronic granulomatous disease, mycobacterial and fungal 
infections.  
 
The major side effects of all interferon therapies include flu-like syndromes, fever, myalgia, 
headache and fatigue. Hypotension, granulocytopenia, and thrombocytopenia can also occur. 




Granulocyte Colony-Stimulating Factor (G-CSF) preparations such as Filgrastim can 
significantly enhance neutrophil functions. A high proportion of HIV-infected patients has 
neutropenia, which considerably increases the risk for bacterial and fungal infections. 
Filgrastim was granted license extension to cover the treatment of persistent neutropenia at an 
advanced stage of HIV infection [11]. In one study conducted at 27 European centers on 
AIDS patients with cytomegalovirus infection, G-CSF (lenograstim) was found to be suitable 
for the treatment of ganciclovir-induced neutropenia [12]. Recently developed recombinant 
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human G-CSF, pegfilgrastim, has been shown to be associated with a lower risk of 
neutropenia-related hospitalizations [13]  
 
G-CSF and Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) are used to 
reverse leukopenia as adjunctive therapy for HIV-associated infections. The GM-CSF 
preparation Sargramostim helps overcome defects in neutrophil and macrophage function due 
to its broad range of effects on lymphocytes, macrophages, neutrophils, and dendritic cells. It 
enhances the antiretroviral activity of zidovudine and stavudine in macrophages and 
ameliorates the hematologic side effects of these agents. Multiple deficiencies are involved in 
the progression of fungal infections in cancer patients with or without neutropenia. Although 
clinical experience is still limited, G-CSF, GM-CSF, and macrophage colony-stimulating 
factor show promise as adjuvant therapy for fungal infections. 
 
CHEMOKINES AND CHEMOKINE MODULATORS  
 
CHEMOKINES have been historically regarded as leukocyte chemoattractants capable of 
regulating cellular trafficking into inflammatory sites. The sobriquet “chemokine” is 
abbreviated from chemotactic cytokine. The major classes of chemokines are constituted by 
the CXC or α chemokines, the CC or β chemokines, the C or γ chemokines, and the CX3C 
chemokines. The nomenclature of the chemokines is based on the spacing of two critical 
cystine residues near the amino terminus, indicating no (CC) or one (CXC) or three CX3C) 
aminoacids acids between the first two cysteins near the amino terminus. The chemokine 
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family has expanded to 80 ligands including CXCL, CCL, XCL and CX3CL chemokines and 
chemokine receptors including CXCR, CCR, XCR and CX3CR 
 
Many erudite reviews on human immunodeficiency virus (HIV) /AIDS etiology and 
manifestation have been published, and these will not be dealt with here. It is noteworthy that 
currently there are more women worldwide who have been infected with HIV than males and 
females account for nearly half of over 40 million people living with HIV [14]. Women are 
more vulnerable to HIV infection than men, and their increased susceptibility has been linked 
to the use of hormonal contraceptives and sexually transmitted diseases. Also, susceptibility 
to HIV varies throughout a women's reproductive life; adolescent girls appear to be most 
vulnerable to HIV due to high-risk sexual behavior and a not fully mature reproductive 
system. In addition, recent studies have indicated increases in the risk of acquiring HIV 
during pregnancy and during the early postpartum period, part of which could be attributed to 
higher levels of progesterone. Successful control of the HIV pandemic requires continuing 
focus on gender. Some of the fundamental issues of HIV transmission have been riddled with 
problems as it is neither feasible to obtain nor examine relevant cells and tissue at the precise 
time of HIV acquisition.  
 
The binding of the HIV envelope glycoprotein gp120 to CD4 and appropriate chemokine 
receptors triggers conformational changes facilitating the fusion of the viral and host cell 
membranes. Chemokine receptors — mainly CCR5 and CXCR4 — have been discovered to 
be necessary as coreceptors for HIV entry [15]. HIV found in the vaginal and rectal mucosa is 
mainly CCR5-dependent. Macrophage-tropic (R5) HIV variants predominantly make use of 
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the CCR5 coreceptors. The T cell-tropic (X4) and dual-tropic (R5X4) HIV strains, generally 
associated with the clinical manifestations of AIDS, emerge after a latency of several years, 
although pathogenesis of the central nervous system and related symptoms are normally 
associated with M-tropic (R5) HIV strains. X4 HIV infection augments the expression of 
chemokines such as MIP-1α (macrophage inflammatory protein) and RANTES (regulated 
upon activation normal T cell expressed and secreted) [16]. 
 
HIV infection can be inhibited by chemokines and chemokine-related molecules that are 
ligands for receptors that function as coreceptors. Chemokine receptors thus represent 
important targets for intervention in HIV and search for molecules that have a therapeutic 
potential as inhibitors of these receptors has been intense [17]. Intervention strategies based 
on chemokine antagonists that could be useful for the therapy of HIV include receptor-ligand 
interaction, prevention of the chemokine-glycosaminoglycan interaction, interfering with the 
signaling pathways that are induced upon receptor activation, and modification of receptor 
pathways [18].  
 
TARGETING CCR5 AND CXCR4 
The chemokine receptors CXCR4 and CCR5 are the main coreceptors used respectively by 
the T-cell-tropic (CXCR4-using, X4) and macrophage-tropic (CCR5-using, R5) HIV for cell 
entry. Several compounds targeting CXCR4 and CCR5 have been advocated recently. The 
idea for the drug class came from the observation that presence of mutated CCR5 can confer 
resistance to HIV infection, even after exposure to numerous high-risk sexual partners. Only 




Modified chemokines with antiviral activity, several low-molecular weight CXCR4 and 
CCR5 antagonistic compounds, have been described. Maraviroc developed by Pfizer as a 
CCR5 antagonist, was licensed in 2007 by the FDA for use in HIV treatment-experienced 
patients harboring only R5 viruses. Another chemokine (CCR5) inhibitor, Aplaviroc or GSK 
873140, was developed by GlaxoSmithKline, but studies were discontinued due to liver 
toxicity concerns. Other companies working on CCR5 antagonists include Pfizer Inc and 
Schering-Plough Corp. 
 
Plerixafor (AMD3100, Mozobil), a bicyclam compound, targets CXCR4 and has a potent 
anti-HIV activity against T-tropic viruses. It is used in combination with G-CSF to enhance 
mobilization of hematopoietic stem cells in transplantation patients with non-Hodgkin’s 
lymphoma or multiple myeloma and has a good safety profile. It has marketing authorization 
in 33 countries worldwide including the EU and USA and is commercially available in 12 
countries. A derivative AMD3451, pyridinylmethyl monocyclam, has been synthesized and 
reported to show dual CCR5/CXCR4 antagonistic activity against both X4 and R5 HIV 
strains [19].  
. 
Most existing HIV drugs work inside the body's immune cells, after the virus has infected and 
can cause anemia, diarrhea and nerve pain. New drugs could provide an important treatment 
option for people with HIV/AIDS, by offering a different mode of action and an improved 
toxicity profile. Both CXCR4 and CCR5 chemokine receptor inhibitors may be needed in 
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combination and even in combinations with antiviral drugs that also target other aspects of the 





Several strategies exist for responding to infection. One mechanism by which the host 
attempts to restrain the infection is through the up-regulation of cytokines. Some cytokines, 
such as IL-1, IL-6, IL-8, IL-18, and TNF, counteract the challenge by worsening the disease 
in an effort to rid the host of infection. Overproduction of proinflammatory cytokines is 
believed to underlie the progression of many inflammatory diseases including rheumatoid 
arthritis, Crohn's disease and endotoxin shock. Many infectious diseases, including HIV, 
influenza H5N1 and malaria can induce deleterious overproduction of proinflammatory 
cytokines.  
 
Intense interest has been generated in developing agents that can block the activity of such 
cytokines. Inhibition of TNF activity has been singularly successful in the treatment of 
autoimmune diseases. Monoclonal antibodies including adalimumab (Humira; Abbott), 
etanercept (Enbrel; Amgen/Wyeth), infliximab (Remicade; Centocor), and Certolizumab 
pegol are used in the treatment of rheumatoid arthritis. An interleukin-1 (IL-1) receptor 
antagonist, Kineret, has also been licensed. Some of these monoclonal antibody products have 
shown promise for applications in disease management in patients with HIV/AIDS [20-21]  
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Another potent TNF inhibitor, thalidomide, has been used in trials in HIV patients [22]. More 
recently, thalidomide and its immunomodulatory imide analogs such as Actimid, 
Lenalidomide , Pomalidomide and Revlimid, have been used as anti-inflammatory drugs.  
 
Pentoxifylline, a methylxanthine usually used in the treatment of peripheral arterial 
circulatory disorders, has been shown to inhibit TNF synthesis. Pentoxifylline has been used 
in HIV for improving certain functions [23]. Currently, clinical trials are ongoing with 
phosphodiesterase inhibitors and small-molecule inhibitors of TNF-converting enzyme that 
specifically interrupt the signaling pathways of TNF. 
TNF plays an important role in defense against bacterial and viral infections. Consequently, 
many patients on anti-TNF drug therapy have shown severe infections such as tuberculosis 
[24]. A variety of other opportunistic fungal infections by Candidia, Aspergillus 
Pneumocystis, Coccidioides, Histoplasma, have also been reported in patients treated with 
anti-TNF monoclonals [25]. 
Sepsis is one of the most common complications in surgical patients and one of the leading 
causes of mortality in intensive care units. Sepsis can be caused by infection with Gram-
negative bacteria, Gram-positive bacteria, fungi, or viruses. Sepsis may, however, also occur 
in the absence of detectable bacterial invasion. In such cases, microbial toxins, particularly 
Gram-negative bacterial endotoxin, and endogenous cytokine release have been implicated as 
initiators and mediators. Septic shock represents the most severe form of host response to 
infection. Despite recent progress in antibiotics and critical care therapy, sepsis is still 
associated with a high mortality rate (~40–50%) and remains the tenth leading cause of death 
in western countries. A number of therapies delaying the onset, and/or reducing the effects of 
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proinflammatory cytokines induced during sepsis are under development. TAK-242 
(Resatorvid), a small molecule antagonist of Toll-like receptor (TLR) 4 signaling, reduces 
lipopolysaccharide (LPS)-induced production of proinflammatory IL-1, IL-6 and TNF-and is 
currently undergoing phase III evaluation [26]. Another compound, E5564 (Eritoran), is a 
synthetic molecule derived from the nonpathogenic Rhodobacter sphaeroides and was 
observed to reduce TNF and IL-6 levels after LPS administration [48]. Eritoran is under 
evaluation in a phase III study in patients with onset of severe sepsis. 
SYNTHETIC IMMUNOMODULATORS 
Microbial pathogens possess a variety of
 
evolutionarily conserved structural motifs known as 
pathogen-associated molecular
 
patterns (PAMPs). These PAMPS are recognized by a family 
of specific TLRs. Around thirteen TLRs exhibiting distinct
 
ligand specificities have been 





to lipopolysaccharide, TLR5 binds to flagellin 
that is part of the flagellum that
 
propels many kinds of bacteria. TLR7 and TLR8 recognize 
imidazoquinoline compounds and single-stranded
 
RNA from viruses, whereasTLR9 binds to 
unmethylated CpG DNA motifs frequently found in the genome of bacteria and viruses.  
 
In humans, TLR7 and TLR9 are expressed on the plasmacytoid dendritic cells (PDC) which 
can rapidly synthesize large amounts IFN-  and IFN-  in response to viral infection. 
Interestingly, TLR7 recognizes synthetic immunomodulators such as Imiquimod, a fully 
synthetic immune response enhancing imidazoquinoline amine [28], that are used against 
viral infections. Imiquimod is marketed as Aldara™ for genital warts caused by human 
papillomavirus (HPV) subtypes number 6 and 11, but is widely used for basal cell carcinoma, 
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actinic keratosis and molluscum contagiosum. It has shown promise in lentigo maligna and 
cutaneous metastases of malignant melanoma.  
 




Antimicrobial peptides (AMPs), also known as host defense peptides (HDPs), are present 
mainly in phagocytic cells
 
of the immune system and are rapidly mobilized. AMPs 
demonstrate potent antimicrobial activity and can kill a wide array of Gram-positive and 
Gram-negative bacteria, enveloped viruses, fungi and parasites through disruption of 
microbial membranes. Of clinical significance is the ability of AMPs to kill multidrug-
resistant microorganisms [29]. Two AMPs have been shown in Phase III clinical trials to be 
effective. Pexiganan, has been developed for topical treatment of patients with mild diabetic 
foot infection and can cure approximately 90% of the patients. The other AMP, Omiganan , 
has shown efficacy in preventing catheter-related infections. 
 
Defensins 
Defensins are polypeptides of the innate immune system produced in response to microbial 
infection in humans and animals. Recent reports have highlighted the anti-HIV activities of 
defensins, whose structure and charge resemble portions of the HIV-1 transmembrane 
envelope glycoprotein gp41. CD8 T cells from long-term non-progressors with HIV infection 
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were found to secrete a cluster of proteins identified as -defensin 1, 2, and 3. A study of 
seronegative women who were exposed
 





extensive -defensin production at both peripheral and mucosal
 
levels. The -
defensin expression level in these seronegative
 
women was 10-fold higher than that of control 
subjects [30].
 
Likewise, overexpression of -defensins in breast milk results
 
in a low rate of 
HIV-1 transmission from mother to infant [31]. 
 
HIV induces -defensin-2 and 3 in human oral epithelial cells which exhibit strong anti-HIV 
activity due
 
to the direct antiviral effect or competition for the chemokine
 
receptors that HIV 
uses to enter the cell [32]. Mother-to-child transmission of HIV is the main source of pediatric 
AIDS. There is a significant relationship between genetic variants of -defensin-1 gene, viral 
load, and mother-to-child transmission of HIV. In mothers, the -52GG genotype is associated 
with low levels of HIV plasma viremia and a lower risk of maternal HIV transmission [33].  
 
Defensins are known to exhibit inhibitory activity against several viruses. Alpha-defensins 
promote uptake of influenza virus by neutrophils and human defensins 5 and 6 are effective in 
neutralizing influenza virus [34]. The expression of murine -defensin was enhanced in 
influenza-infected lungs, trachea and nasal mucosa [35] and treatment of cell cultures with 
human neutrophil peptides   soon after infection - resulted in marked inhibition of influenza 
virus replication and viral protein synthesis [36]. BK virus is a polyomavirus that establishes a 
lifelong persistence in most humans. Studies have shown that human alpha-defensins can 
inhibit BKV infection [37], inhibit adenovirus infection [38], and -defensins and human -





The conventional treatment of infectious agents is increasingly encountering antimicrobial 
resistance. This has led to an intense search for novel treatment modalities for infectious 
diseases including therapeutic use of biologically manufactured cytokines and cytokine 
inhibitors. The appeal of biological response modifiers is inherent in modes of action that are 
distinctly different from the direct microbicidal action of established antibiotic, antiviral, 
antifungal and antiparasitic drugs. Elucidation of mechanisms underlying the inhibitory 
activity of chemokines has been instrumental in the rational design of anti-HIV chemokine 
drugs such as Maraviroc and other analogs. The immune-based therapies in combination with 
antimicrobial drugs, such as interferons and ribavirin for viral hepatitis have attracted much 
attention. Recognition of toll-like receptors by synthetic immunomodulators such as 
Imiquimod are used for certain viral infections. New methodologies have the potential to 
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